Mizuho Securities reiterated a Buy rating for a Group A strep vaccine, noting benefits from Trump-era tariffs and onshoring trends.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mizuho Securities reiterated a Buy rating for a Group A strep vaccine, noting benefits from Trump-era tariffs and onshoring trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Mizuho Securities
Japanese investment banking company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- Mizuho Securities lowered its price target on Lam Research stock, while Berenberg Bank set a high target and Citigroup reiterated a buy rating.
- Mizuho Securities raised its price target on Dell Technologies.
- Multiple analyst firms, including Needham, Mizuho, and Zacks, issued rating changes and coverage updates for Harmony Biosciences.
- Mizuho Securities raised its price target for Element Solutions Inc. on October 22, 2026.